03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Extavia* : | |
Type | Medicine Non Marketed |
Originator | B |
Agent | Khalil Fattal & Fils |
Distributor | Khalil Fattal & Fils |
Laboratory | Novartis |
Responsible Party | Bayer Schering Pharma AG for Novartis Pharma AG Switzerland |
Origin | Germany |
Manufacturer | Bayer Schering Pharma AG |
Origin | Germany |
ATC | L03AB08 |
Revision Date | 12/07/2010 |
Extavia* :
Extavia* :
Extavia* :
Extavia* :
Extavia* :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Extavia* :
Extavia* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Not known |
Abscess | Not known |
Affect lability | Uncommon |
Alopecia | Common |
ALT increased | Not known |
Anaemia | Common |
Anaphylactic reactions | Rare |
Anxiety | Not known |
Arthralgia (Pain joint) (Joint ache) | Very Common |
AST increased | Not known |
Asthenia | Not known |
Back pain | Not known |
Blood bilirubin increased | Common |
Blood glucose decreased | Not known |
Blood triglycerides increased | Uncommon |
Bronchospasm | Rare |
Capillary leak syndrome | Not known |
Cardiomyopathy | Rare |
Chest pain | Not known |
Chills | Not known |
Confusional state | Common |
Conjunctivitis | Not known |
Constipation | Not known |
Cough | Not known |
Decreased appetite | Rare |
Depression | Not known |
Diarrhoea (Diarrhea) | Not known |
Dizziness | Not known |
Dysmenorrhoea | Not known |
Dyspnoea (dyspnea) | Not known |
Erectile dysfunction | Not known |
Gamma-GT increased | Uncommon |
Glomerulosclerosis | Uncommon |
Haemolytic uraemic syndrome (HUS) | Rare |
Headache | Not known |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Rare |
Hepatitis | Uncommon |
Hyperhidrosis | Not known |
Hypertension | Not known |
Hyperthyroidism | Rare |
Hypertonia | Not known |
Hypothyroidism | Common |
Infection | Not known |
Influenza-like illness | Not known |
Injection site atrophy | Not known |
Injection site haemorrhage | Not known |
Injection site hypersensitivity | Not known |
Injection site inflammation | Not known |
Injection site mass | Not known |
Injection site necrosis | Not known |
Injection site oedema | Not known |
Injection site pain | Not known |
Injection site reaction | Not known |
Insomnia | Not known |
Leukocyte count decreased (White blood cell count decreased) | Not known |
Liver injury | Rare |
Lymphadenopathy | Not known |
Lymphocyte count decreased | Not known |
Malaise | Not known |
Menorrhagia | Common |
Menstrual disorder | Not known |
Metrorrhagia | Not known |
Micturition urgency (Urinary urgency) | Not known |
Migraine | Not known |
Muscle weakness | Not known |
Myalgia | Very Common |
Nausea | Not known |
Nephrotic syndrome | Uncommon |
Neutrophil count decreased | Not known |
Oedema peripheral | Not known |
Otalgia (Earache) (Ear pain) | Not known |
Pain | Not known |
Pain in extremity (Pain in limb) | Not known |
Palpitations | Not known |
Pancreatitis | Rare |
Paraesthesia (paresthesia) | Not known |
Pollakiuria (Urinary frequency) | Not known |
Protein urine present | Not known |
Pruritus | Common |
Pyrexia | Not known |
Seizures | Uncommon |
Sinusitis | Not known |
Skin discolouration (Dyschromia) | Uncommon |
Skin disorders | Not known |
Skin rash | Not known |
Suicide attempt | Uncommon |
Tachycardia | Common |
Thrombocytopenia (Thrombopenia) | Uncommon |
Thrombotic microangiopathy | Rare |
Thrombotic thrombocytopenic purpura (TTP) | Rare |
Thyroid disorder | Rare |
Upper respiratory tract infection | Not known |
Urinary incontinence | Not known |
Urinary retention | Not known |
Urticaria | Common |
Vasodilation | Not known |
Visual disturbance | Not known |
Vomiting | Not known |
Weight decreased (Weight loss) | Common |
Weight increased (weight gain) | Common |
Extavia* :
NB : Products With Same Indication |
Different Units By MoH Code
Extavia* MoH 6560 :
Form | Powder and solvent for solution for injection |
Packaging | Pre-filled Syringe + Vial |
Package Size | 15+15x1.2ml |
Strength | 300µg |
Storage Condition | <25°C Do not freeze |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 166975/11 |
Submission date | 01/01/2011 |
Registration Year | 2012 |
Archived Date | 2016 |
Price Comparison
● Country: | Italy | |
● Package Size: | 15 | |
● Public Price: | 1275.04 EUR | ( 123,520,775.04 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 85,0027 EUR | ( 8,234,460.00 LBP ) |
● Pricing Date: | 17/12/2019 | |
● Type: | Medicine Authorised |
● Country: | Denmark | |
● Package Size: | 15 sæt | |
● Public Price: | 8341.4 DKK | ( 108,238,006.40 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 556,0933 DKK | ( 7,214,656.00 LBP ) |
● Pharmacy Price: | 6196.71 DKK | ( 80408508.96 LBP ) |
● Reference: | Danish Medicine Agency | |
● Pricing Date: | 19/05/2021 | |
● Type: | Medicine Authorised |
● Country: | Abu Dhabi | |
● Package Size: | 15x(1 Powder Vial + 1 PFS Solvent) | |
● Public Price: | 4120.51 AED | ( 99,555,642.11 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 274,7007 AED | ( 6,620,114.00 LBP ) |
● Pharmacy Price: | 3583.05 AED | ( 86570071.05 LBP ) |
● Pricing Date: | 27/01/2021 | |
● Type: | Medicine Authorised |
● Country: | Spain | |
● Package Size: | 15 viales + 15 jeringas precargadas de disolvente | |
● Public Price: | 957.75 EUR | ( 92,782,989.00 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 63,85 EUR | ( 6,103,188.00 LBP ) |
● Reference: | Agencia Española de Medicamentos y Productos Sanitarios | |
● Pricing Date: | 06/05/2021 | |
● Type: | Medicine Authorised |
● Country: | Cyprus | |
● Package Size: | 15 VIALS+ | |
● Public Price: | 763.89 EUR | ( 74,002,607.64 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 50,926 EUR | ( 4,843,800.00 LBP ) |
● Reference: | Cyprus Minister of Health | |
● Pricing Date: | 30/01/2018 | |
● Type: | Medicine Non Marketed |
● Country: | France | |
● Package Size: | 15+15x1,2ml | |
● Public Price: | 754.77 EUR | ( 73,119,098.52 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 50,318 EUR | ( 4,843,800.00 LBP ) |
● Reference: | ansm | |
● Pricing Date: | 30/09/2019 | |
● Type: | Medicine Non Marketed |
● Country: | UK | |
● Package Size: | 15 | |
● Public Price: | 596.63 GBP | ( 67,806,402.87 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 39,7753 GBP | ( 4,432,311.00 LBP ) |
● Reference: | DMD | |
● Pricing Date: | 08/03/2021 | |
● Type: | Medicine Authorised |
● Country: | Czech Republic | |
● Package Size: | 15+15x1,2ml ISP | |
● Public Price: | 16607.96 CZK | ( 63,425,799.24 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 1107,1973 CZK | ( 4,227,633.00 LBP ) |
● Reference: | SUKL | |
● Pricing Date: | 28/02/2020 | |
● Type: | Medicine Authorised |
● Country: | Sweden | |
● Package Size: | 15 | |
● Public Price: | 6424.51 SEK | ( 54,017,280.08 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 428,3007 SEK | ( 3,598,624.00 LBP ) |
● Pharmacy Price: | 6253.2 SEK | ( 52576905.6 LBP ) |
● Pricing Date: | 08/10/2018 | |
● Type: | Medicine Non Marketed |
● Country: | Greece | |
● Package Size: | 15 | |
● Public Price: | 543.97 EUR | ( 52,697,637.72 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 36,2647 EUR | ( 3,487,536.00 LBP ) |
● Exfactory Price: | 463.84 EUR | |
● Pharmacy Price: | 470.81 EUR | ( 45610189.56 LBP ) |
● Reference: | National Organization for Medicines | |
● Pricing Date: | 20/08/2020 | |
● Type: | Medicine Authorised |
● Country: | Norway | |
● Package Size: | 15 | |
● Public Price: | 6437.3 NOK | ( 52,167,879.20 LBP ) |
● Pack size unit used: | 15 | |
● Cost/Unit: | 429,1533 NOK | ( 3,476,616.00 LBP ) |
● Pharmacy Price: | 5020.45 NOK | ( 40685726.8 LBP ) |
● Reference: | Norwegian Medicine Agency | |
● Pricing Date: | 01/04/2020 | |
● Type: | Medicine Withdrawn |
● Country: | Finland |
● Package Size: | 15x(3ml + 1.2ml) |
● Reference: | Kela |
● Pricing Date: | 22/04/2021 |
● Type: | Medicine Non Marketed |
● Country: | The Netherlands |
● Package Size: | 15 |
● Reference: | Zorginstituut Nederland |
● Pricing Date: | 15/06/2019 |
● Type: | Medicine Non Marketed |
Note
You have to register to view this info
Drop File